Edgar Filing: Epizyme, Inc. - Form 4

Epizyme, Ir Form 4 May 12, 20 FORN Check t if no lon subject Section Form 4 Form 5 obligati may con <i>See</i> Inst 1(b).	16 A 4 UNITED his box nger to 16. or Staten Filed pur Section 176	MENT OF rsuant to S (a) of the F	Wa F CHAN Section 1 Public U	shington NGES IN SECU (6(a) of ti (tility Ho	h, D.C. 2 I BENEI RITIES he Secur Iding Co	0549 FICL	AL OWN	OMMISSION ERSHIP OF Act of 1934, 935 or Section	OMB Number: Expires: Estimated a burden hour response	~	
	Address of Reporting	Person <u>*</u>	Symbol	er Name an ne, Inc. [I		or Trad		. Relationship of I ssuer			
	(First) (YME, INC., 400 LOGY SQUARE	Middle)	3. Date o	of Earliest 7 Day/Year)	_	1		Director _X Officer (give t elow)) Owner r (specify	
				onth/Day/Year) Applicable _X_Form					or Joint/Group Filing(Check e) I by One Reporting Person by More than One Reporting		
(City)	(State)	(Zip)	Tab	le I - Non-	Derivativ	e Secu		red, Disposed of,	or Beneficial	v Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ed Date, if	3.		ties A sed of	cquired (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, par value \$0.0001	05/09/2016			Code V	Amount 1,682		Price (<u>1)</u>	(Instr. 3 and 4) 21,935	D		
Common Stock, par value \$0.0001	05/09/2016			М	778	A	<u>(1)</u>	22,713	D		
Common Stock, par value \$0.0001	05/09/2016			S <u>(2)</u>	617	D	\$ 9.5684 (<u>3)</u>	22,096	D		

Edgar Filing: Epizyme, Inc. - Form 4

Common Stock, par value \$0.0001	05/09/2016	S <u>(2)</u>	76	D	\$ 10.1277 (4)	22,020	D
Common Stock, par value \$0.0001	05/09/2016	S <u>(2)</u>	320	D	\$ 10.1277 (4)	21,700	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	Transaction of Derivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Pr Deriv Secu (Inst
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Units	<u>(1)</u>	05/09/2016		М		1,682	(5)	(5)	Common Stock	1,682	\$
Restricted Stock Units	<u>(1)</u>	05/09/2016		М		778	(6)	(6)	Common Stock	778	\$

Reporting Owners

Reporting Owner Name / Address	Relationships							
i o	Director	10% Owner	Officer	Other				
Singer Andrew E. C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139			EVP & CFO					

Signatures

/s/ Adriana Sullivan attorney-in-fact

05/11/2016

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting.
- (2) The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person to cover taxes associated with the vesting of his restricted stock.

(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.04 per share to \$10.03 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$10.04
 (4) per share to \$10.18 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on
(5) February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person.

This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on
(6) February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.